Compare

Retatrutide vs Tirzepatide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Retatrutide

381 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 45% · Mixed 38% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
-72
Digestive comfort
-134
Skin appearance
-74
Appetite control
-44
Energy
-40

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
-156
Flushing
-54
Headache
-109
GI discomfort
-49
Dizziness
-41

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.025–2 mg

0.025–0.05 mg
1
0.05–0.1 mg
9
0.1–0.2 mg
12
0.2–0.4 mg
17
0.4–0.6 mg
9
0.6–1 mg
6
1–2 mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing25stacking38side effects11retatrutide14

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 31% more positive, and 15% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 84 repeat reporters

Tirzepatide

2335 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 49% · Mixed 36% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Lean mass
50
Joint comfort
106
Recovery
68
Digestive comfort
86
Skin appearance
88

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Appetite loss
146
Injection site reaction
186
Anxiety
33
Flushing
82
Headache
88

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.2–5 mg

0.2–0.4 mg
3
0.4–0.6 mg
13
0.6–1 mg
17
1–2 mg
9
2–3 mg
10
3–5 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing19stacking27side effects15tirzepatide18

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 29% more positive, and 19% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 514 repeat reporters

Sources (16)

Published sources linked on the Retatrutide and Tirzepatide wiki pages.

  1. PubMed

    Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

    Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023

    Source
    Wiki study page →
  2. PubMed

    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

    Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    Retatrutide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. ClinicalTrials.gov

    Retatrutide studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  5. PubMed

    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

    Jastreboff AM, Kaplan LM, Frías JP, et al. The New England journal of medicine. 2023

    Source
    Wiki study page →
  6. PubMed

    Retatrutide-A Game Changer in Obesity Pharmacotherapy

    Katsi V, Koutsopoulos G, Fragoulis C, et al. Biomolecules. 2025

    Source
    Wiki study page →
  7. FDA Drug Label

    MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2022

    Source
    Wiki study page →
  8. PubMed

    Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022

    Source
    Wiki study page →
  9. ClinicalTrials.gov

    Tirzepatide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  10. PubMed

    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

    Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021

    Source
    Wiki study page →
  11. PubMed

    Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).

    Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024

    Source
    Wiki study page →
  12. FDA Drug Label

    ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2023

    Source
    Wiki study page →
  13. PubMed

    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

    Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023

    Source
    Wiki study page →
  14. PubMed

    Tirzepatide for Obesity Treatment and Diabetes Prevention

    Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025

    Source
    Wiki study page →
  15. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →
  16. PubMed

    Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

    Aronne LJ, Ahmad NN, Fletcher M, et al. JAMA. 2024

    Source
    Wiki study page →